Related references
Note: Only part of the references are listed.Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm
Stefania Mitola et al.
BLOOD (2008)
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
Helena Stabile et al.
BLOOD (2007)
Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation
Julie B. Sneddon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein
Hong Namkoong et al.
BMC CANCER (2006)
Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells
Lorna C. Ewan et al.
TRAFFIC (2006)
The biology of vascular endothelial growth factors
T Tammela et al.
CARDIOVASCULAR RESEARCH (2005)
Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor
L Zilberberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning
MK Khokha et al.
NATURE GENETICS (2003)
Drm/Gremlin transcriptionally activates p21Cip1 via a novel mechanism and inhibits neoplastic transformation
B Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy
DWP Lappin et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules
UA Vitt et al.
MOLECULAR ENDOCRINOLOGY (2001)
Share Paper
